

A

	Randomization process	Deviation from the intended interventions	Missing outcome data	Measurement of the outcome	Selection of the reported result	Overall
<b>Analgesics</b>						
Espinoza, 2022	●	●	●	●	●	●
<b>Chemotherapy</b>						
Wildiers, 2018	●	●	●	●	●	●
<b>Nutritional supplement</b>						
Orkaby, 2022	●	●	●	●	●	●
Chakravarthy, 2020	●	●	●	●	●	●
Badrasawi, 2016	●	●	●	●	●	●
Buigues, 2016	●	●	●	●	●	●

●	Low risk
●	Moderate risk
●	High risk

B

	Selection	Comparability	Outcome	New user design	Overall
<b>Analgesics</b>					
Orkaby, 2022	●	●	●	●	●
Orkaby, 2021	●	●	●	●	●
<b>Cardiometabolic medication</b>					
Veronese, 2019	●	●	●	●	●
Wang, 2017	●	●	●	●	●
LaCroix, 2008	●	●	●	●	●
<b>Chemotherapy</b>					
Brouwers, 2016	●	●	●	●	●
<b>CNS-active medication</b>					
Lee, 2021	●	●	●	●	●
Cil, 2019	●	●	●	●	●
Aprahamian, 2019	●	●	●	●	●
Lakey, 2012	●	●	●	●	●
<b>Hormonal therapy</b>					
Stollo, 2013	●	●	●	●	●
Cheung, 2016	●	●	●	●	●
Cheung, 2018	●	●	●	●	●

  

●	Low risk
●	Moderate risk
●	High risk

**Fig. S2.** Quality of evidence for the studies: (A) randomized controlled trial studies and (B) cohort studies.